EUCTR2020-002728-35-HU进行中（未招募）1 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia- An open-label randomized controlled study
Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium0 个研究点目标入组 150 人开始时间: 2020年8月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Age: 18 to 74 years (at the time of informed consent)
- •2)Gender: Male or female
- •3)Patients who meet all of the following criteria 1), 2), and 3) at the time of enrolment
- •oPatients with SARS-CoV-2-positive airway specimens such as nasopharyngeal swab, nasal aspirate, or airway aspirate by RT-PCR test
- •oPatients with new lung lesions on chest images
- •oPatients with a fever of 37.5°C or more
- •4)For premenopausal female patients, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug
- •5)Patients who understand the contents of this study and are able to provide written consent by themselves without assistance, or as appropriate with their assent and consent of their parents
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1)Fever (37.5°C) more than 10 days after the onset of fever
- •2)Patients with SpO2 less than 95% without oxygen therapy
- •3)Patients who show increased procalcitonin levels before the start of study drug administration or are suspected to have concurrent bacterial infection
- •4)Patients with suspected concomitant fungal infections prior to initiation of study drug.
- •5)Patients with concurrent congestive heart failure (NYHA III-IV)
- •6)Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification
- •7)Patients with renal impairment requiring dialysis
- •8)Patients with disturbed consciousness such as disturbed orientation
- •9)Pregnant or possibly pregnant patients
- •10)Female patients who are woman of childbearing potential and unable to consent to the use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation.
- •11)Male patients who are unable to consent to the use of the barrier method of contraception (condom) the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm from the start up until 90 days after the end of favipiravir administration.
- •12)Female patients who intend to breastfeed from the start of favipiravir administration until 7 days after discontinuation of favipiravir administration
- •13)Patients with hereditary xanthinuria
- •14)Patients who have previously been diagnosed with hyperuricemia (> 1 mg/dL) or xanthine urinary calculi
- •15)Patients with a history of gout or on treatment for gout or hyperuricemia
- •16)Patients receiving immunosuppressants
- •17)Patients who have received interferon-alpha or drugs with reported antiviral activity against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 9 days after fever onset (37.5°C or more)
- •18)Patients in whom this episode of infection is a recurrence or a reinfection with the SARS-CoV-2 infection
- •19)Patients who have previously received favipiravir (T-705a)
- •20)Other patients judged ineligible by the investigator, sub-investigator, or assigned physician
研究者
相似试验
进行中（未招募）
1 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without PneumoniaCOVID-19 Patients without PneumoniaEUCTR2020-005214-18-LTVilnius University Hospital Santaros klinikos75
进行中（未招募）
1 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild PneumoniaCOVID-19 Patients with Mild PneumoniaEUCTR2020-005128-12-LTVilnius University Hospital Santaros klinikos96
已完成
2 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID 19 Patients without PneumoniaCOVID-19COVID-19 Patients without PneumoniaSARS-CoV-2TCTR20200514001Faculty of Medicine, Siriraj Hospital93
已完成
不适用
Investigation on the efficacy and safety of favipiravir in patients who are infected or strongly suspected of being infected with Ebola virusEbola virus diseaseJPRN-UMIN000016101ational Center for Global Health and Medicine5
招募中
3 期
Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19IRCT20200428047228N1Quality Improvement of Intensive Care Research Center- Shahid Beheshti University50